Viability assessment with MRI is superior to FDG-PET for viability: Pro

Journal of Nuclear Cardiology

Volumn 17, Issue 2, 2010, Pages 292-297

  Maddahi, Jamshid ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; GADOLINIUM; GADOLINIUM PENTETATE;

CLINICAL EFFECTIVENESS; CONTRAST ENHANCEMENT; CORONARY ARTERY DISEASE; HEART CONTRACTION; HEART MUSCLE; HEART MUSCLE METABOLISM; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; IMAGE PROCESSING; IMAGE QUALITY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION EXPOSURE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CONTRAST MEDIA; CORONARY ARTERY DISEASE; FLUORODEOXYGLUCOSE F18; HEART; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PERFUSION; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77953321486     PISSN: 10713581     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12350-010-9201-y     Document Type: Review

References (34)

1. Rahimtoola SH. The hibernating myocardium. Am Heart J 1989; 117:211-21.
2. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med 1998;339:173-81.
3. Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984;16:167-72.
4. Schaefer S, Malloy CR, Katz J, Parkey RW, Buja LM, Willerson JT, et al. Gadolinium-DTPA-enhanced nuclear magnetic resonance imaging of reperfused myocardium: Identification of the myocardial bed at risk. J Am Coll Cardiol 1988;12:1064-72.
5. Judd RM, Lugo-Olivieri CH, Arai M, Kondo T, Croisille P, Lima JA, et al. Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts. Circulation 1995;92:1902-10.
6. Kim RJ, Chen EL, Lima JA, Judd RM. Myocardial Gd-DTPA kinetics determine MRI contrast enhancement and reflect the extent and severity of myocardial injury after acute reperfused infarction. Circulation 1996;94:3318-26.
7. Flacke SJ, Fischer SE, Lorenz CH. Measurement of the gado-pentetate dimeglumine partition coefficient in human myocardium in vivo: Normal distribution and elevation in acute and chronic infarction. Radiology 2001;218:703-10.
8. Rehwald WG, Fieno DS, Chen EL, Kim RJ, Judd RM. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation 2002;105: 224-9.
9. Klein C, Nekolla SG, Balbach T, Schnackenburg B, Nagel E, Fleck E, et al. The influence of myocardial blood flow and volume of distribution on late Gd-DTPA kinetics in ischemic heart failure. J Magn Reson Imaging 2004;20:588-93.
10. Klein C, Schmal TR, Nekolla SG, Schnackenburg B, Fleck E, Nagel E. Mechanism of late gadolinium enhancement in patients with acute myocardial infarction. J Cardiovasc Magn Reson 2007;9:653-8.
11. Saraste A, Nekolla S, Schwaiger M. Contrast-enhanced magnetic resonance imaging in the assessment of myocardial infarction and viability. J Nucl Cardiol 2008;15:105-17.
12. Wagner A, Mahrholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: An imaging study. Lancet 2003;361:359-60.
13. Perazella MA. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Saf 2008;3:67-75.
14. Voipio-Pulkki L, Nuutila P, Knuuti J, et al. Heart and skeletal muscle glucose disposal in type 2 diabetic patients as determined by PET. J Nucl Med 1993;34:2064-7.
15. Ohtake T, Yokoyama I, Watanabe T, et al. Myocardial glucose metabolism in NIDDM patients evaluated by FDG-PET. J Nucl Med 1995;36:456-63.
16. 18F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction. J Nucl Med 2001;42:1730-6.
17. 18F-labelled fluorode-oxyglucose and N-13 ammonia. Circulation 1983;314:884-8.
18. Tillisch J, Brunken R, Marshall R, Schwaiger M, Phelps M, Schelbert H. Reversibility of cardiac wall motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884-8.
19. Maddahi J, Heinrich S, Brunken R, Di Carli M. Role of thallium-201 and PET imaging in evaluation of myocardial viability and management of patients with CAD and LV dysfunction. J Nucl Med 1994;35:707-15.
20. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000;343:1445-53.
21. Selvanayagam JB, Kardos A, Francis JM, Wiesmann F, Petersen SE, Taggart DP, et al. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation 2004;110:1535-41.
22. Van Hoe L, Vanderheyden M. Ischemic cardiomyopathy: Value of different MRI techniques for prediction of functional recovery after revascularization. AJR Am J Roentgenol 2004;182:95-100.
23. Kuhl HP, Lipke CS, Krombach GA, Katoh M, Battenberg TF, Nowak B, et al. Assessment of reversible myocardial dysfunction in chronic ischaemic heart disease: Comparison of contrasten-hanced cardiovascular magnetic resonance and a combined positron emission tomography-single photon emission computed tomography imaging protocol. Eur Heart J 2006;27:846-53.
24. Lauerma K, Niemi P, Hanninen H, Janatuinen T, Voipio-Pulkki LM, Knuuti J, et al. Multimodality MR imaging assessment of myocardial viability: Combination of first-pass and late contrast enhancement to wall motion dynamics and comparison with FDG PET-initial experience. Radiology 2000;217:729-36.
25. Eitzman D, Al-Aouar Z, Kanter HL, vom Dahl J, Kirsh M, Deeb GM, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992;20:559-65.
26. Di Carli MF, Davidson M, Little R, Khanna S, Mody FV, Brunken RC, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994;73:527-33.
27. Lee KS, Marwick TH, Cook SA, Go RT, Fix JS, James KB, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 1994;90:2687-94.
28. vom Dahl J, Altehoefer C, Sheehan FH, Buechin P, Schulz G, Schwarz ER, et al. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease. J Nucl Med 1997;38:742-8.
29. Di Carli MF, Maddahi J, Rokhsar S, Schelbert HR, Bianco-Batlles D, Brunken RC, et al. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: Implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg 1998;116:997-1004.
30. Huitink JM, Visser FC, Bax JJ, van Lingen A, Groenveld AB, Teule GJ, et al. Predictive value of planar 18F-fluorodeoxyglucose imaging for cardiac events in patients after acute myocardial infarction. Am J Cardiol 1998;81:1072-7.
31. Beanlands R, deKemp R, Smith S, Johansen H, Ruddy T. FDG PET imaging alters clinical decision making in patients with impaired ventricular function. Am J Cardiol 1997;79:1092-5.
32. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998;97:765-72.
33. Roes SD, Kelle S, Kaandorp TA, Kokocinski T, Poldermans D, Lamb HJ, et al. Comparison of myocardial infarct size assessed with contrast-enhanced magnetic resonance imaging and left ventricular function and volumes to predict mortality in patients with healed myocardial infarction. Am J Cardiol 2007;100:930-6.
34. Bello D, Fieno DS, Kim RJ, Pereles FS, Passman R, Song G, et al. Infarct morphology identifies patients with substrate for sustained ventricular tachycardia. J Am Coll Cardiol 2005;45:1104-8.